Preclinical testing at The Ohio State University found Telomir-Zn inhibited growth of canine and human osteosarcoma cell lines, prompting the company to explore a possible in-vivo study in dogs with naturally occurring tumors.
|Articles|May 13, 2009
Elanco, Starpharma ink deal to develop new animal-health products
Greenfield, Ind. -- Elanco Animal Health signed a deal with Australia-based Starpharma Holding Ltd. this week to collaborate on the development of new animal-health products.
Advertisement
Greenfield, Ind.
-- Elanco Animal Health signed a deal with Australia-based Starpharma Holding Limited this week to collaborate on the development of new animal-health products.
Advertisement
The collaborative research, license and commercialization agreement gives Elanco access to Starpharma’s dendrimer technology. Dendrimers are considered a unique class of polymers that play a role in nanotechnology as carrier molecules and building blocks.
Under the agreement, Starpharma will receive revenue from research fees and is eligible for milestone payments and royalties on the sale of any product developed, the companies say in a prepared statement. Elanco will receive exclusivity within the animal-health field. Terms were not disclosed.
Starpharma retains all rights to use the technology outside Elanco's specific field of interest, including all uses in humans, and continues to work to add to its portfolio of partners for drug delivery and dendrimer technology more widely.
Advertisement
Related to this article
Caroline Cox, LSW, MSW, and Erika Krick, VMD, DACVIM (Oncology), discuss the role of veterinary social workers in supporting clients, communicating with veterinary teams, and helping practices address the human side of veterinary care in this Q&A from an interview at the 2026 Fetch National Harbor Veterinary Conference.
After more than 20 years of work toward its first rhino birth, the Texas ranch has now welcomed 3 calves in 3 years.
Two notable pet-industry acquisitions closed in September. One bringing AI-powered clinical documentation into IDEXX's software ecosystem, the other marking the first acquisition for fresh-food brand The Farmer's Dog.
New leadership moves, recognition, and achievement.
In a keynote address at the 2026 Fetch National Harbor Veterinary Conference, Jessica Pritchard, VMD, MS, DACVIM (SAIM), shared research showing that many owners decline vaccines because they do not think their pet needs them, and discussed ways veterinary teams can address those concerns.
Alyssa Mages, BS, CVT, FVTE, outlines key considerations for veterinary technicians during triage, from rapid patient assessment and prioritization to client communication and team coordination, in this interview from the 2026 Fetch National Harbor Veterinary Conference.
In a session at the 2026 Fetch National Harbor Veterinary Conference, Nathanael Oster, VMD, MBA, walked attendees through the biology, diagnosis, and treatment of the flea tapeworm in dogs and cats, including why cats are affected more often than dogs.
Advertisement
Advertisement
Trending on dvm360
1
Why pet owners decline vaccines: Survey insights and strategies for navigating hesitancy
2
Recent acquisitions: IDEXX buys CoVet, The Farmer's Dog acquires Woof
3
Paws and profits: Schwarzman AMC names zoological department head, Mars names chief digital and information officer, and more updates
4
Veterinary triage for technicians: Assessing urgency, communicating with clients, and coordinating the team
5